Very undervalued stock. 52 Week High was $46.00 52 Week Low was $3.22 Revenue for the 4th quarter of 2018 was $35.5 million, an 739% increase year over year. Total revenue for the year is $96.4 million. Could do 2x-3x from this level.
Key data presentations at ECCMID 2019 include:
Integrated Symposium Presentations
•“Update on acute bacterial skin and skin...
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration.
Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
$CRBP BIO STOCK >200 MA Break @ 7.08 > Median Analyst Target 26+
Chart is setting up with the 200 MA break for a early set up to the Golden Cross, as the 50 MA is edging up. The stock will Blue Sky with a 11 break. Most Analysts have a target over 26 +.
With Data coming and potential approvals could be " the excuse" to what the chart is...
BIOTECH stocks look as though they have quite a bit f upside to go. what is most interesting is that the S&P and dow generally seem to be nearing a top, but this chart indicates much more bull-side momentum. Im very interested to see how this all pans out. My guess is tactical asset allocation and active investing will soon come back into the fray